The Food and Drug Administration (FDA) has granted Orphan Drug designation to AR-501 (gallium citrate; Aridis Pharmaceuticals, Inc), an investigational treatment for chronic bacterial lung infections in patients with cystic fibrosis (CF).
AR-501, an inhaled formulation of gallium citrate, is a small molecule anti-infective with broad spectrum activity against Gram-negative and Gram-positive bacteria in vitro, including antibiotic-resistant strains. Gallium works as an iron analogue and is believed to inhibit iron-dependent synthetic and metabolic pathways required for disease progression. The inhaled formulation is being developed as a self-administered weekly treatment.
The Company is currently investigating AR-501 in a phase 1/2a clinical trial funded by the Cystic Fibrosis Foundation. Phase 1 trial data is expected to be reported in the first quarter of 2020 and phase 2a data is expected in the second quarter of 2021.
For more information visit aridispharma.com.
This article originally appeared on MPR